Frontier Medicines to Present at Credit Suisse 31st Annual Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in a fireside chat at the Credit Suisse 31^st Annual Healthcare Conference at 9:10 a.m. PT on November 8, 2022 in Rancho Palos Verdes, CA.

A live audio webcast of the event will be available for access in the News & Media section of Frontier’s website (LINK). An archived replay will be accessible for 30 days following the event.

About Frontier Medicines
Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to potentially develop groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer. The company’s lead program is focused on KRAS^G12C and is distinct in that it targets direct inhibition of both the activated and inactive forms of KRAS^G12C. This KRAS mutation is found most prevalently in patients with non-small cell lung, colorectal, and pancreatic cancers. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.

Investor and Media Relations Contact:
Victoria Fort
VP, Corporate Affairs
202.361.0445
victoria.fort@frontiermeds.com